FDA Signals Shift On CBD In Healthcare, But Industry Says It’s Not Enough

The FDA has opened a narrow new lane for certain hemp-derived CBD products in healthcare, but the move stops well short of creating a durable framework for the wider market.

In a memo dated April 1, the agency said it does not intend to enforce certain provisions of the Federal Food, Drug, and Cosmetic Act against an orally administered, hemp-derived CBD product solely because it contains CBD, provided several conditions are met. Those conditions include supplement-style labeling, lack of contamination, packaging that is not attractive to children, and provision to a beneficiary through a program of medical items or services payable under Title XVIII of the Social Security Act under the direction of a treating physician.

The memo also makes clear that FDA authority over CBD products remains intact, and that the applicable regulatory framework still depends on the type of product involved.

Thomas Winstanley, GM and EVP of Edibles.com, called the move “a meaningful, if incremental, step toward regulatory clarity.”

He added that the policy “remains narrowly scoped and stops short of establishing a durable framework for the broader market.”

That tension is likely to define the industry’s response.

For hemp operators and investors, the memo offers another sign that federal agencies are inching toward a more workable approach in tightly controlled settings tied to healthcare and research. But it does not create a broad national CBD marketplace, and it does not resolve the legal uncertainty still hanging over major parts of the hemp category. Marijuana Moment, which first reported on the memo, similarly described the action as limited and tied to the new Medicare-related initiative rather than a comprehensive rewrite of federal cannabinoid policy.

In other words, the FDA has provided a small opening. The broader fight over what a lasting hemp framework should look like is still waiting on Congress.

Photo by CBD Infos on Unsplash